Looks like a piece of shit to me , profits are going down, debt is going up. 8 dollars off its 5 year high. Insiders are selling
Novartis AG
NYSE: NVS
If you look at my thread have more information about this stock
Novartis AG (NVS) is seeing green these days. Currently, NVS is trading at $88.43 and the avg recommendation for the stock is Strong Buy. while the current analyst price target stands at $104.00.
To add more color to this target, the company’s high over the last year is $99.84 and the low is $69.18. Over the last 52 weeks, NVS is down -11.43% while the S&P 500 is down -0.75%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, NVS reported a profit of $8.99 billion. Novartis AG also saw revenues increase to $12.71 billion. In addition, NVS has free cash flow of $2.29 billion as of 03-2020 The company’s EBITDA came in at $2.74 billion which compares well with its peers.
I just sold 5000 shares of this yesterday and will but more.
Novo Nordisk to acquire Corvidia Therapeutics and expand presence in cardiovascular disease
Category: More News Published on Thursday, 11 June 2020 17:18 Hits: 255
BAGSVAERED, Denmark I June 11, 2020 I Novo Nordisk A/S today announced that it has entered into a definitive agreement to acquire Corvidia Therapeutics Inc., a privately held, clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases.
Corvidia Therapeutics’ lead candidate, ziltivekimab, a fully human monoclonal antibody directed against Interleukin-6 (IL-6), is being developed to reduce the risk of major adverse cardiovascular events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation.
Under the terms of the agreement, Novo Nordisk will acquire all outstanding shares of Corvidia Therapeutics for an upfront payment of 725 million US dollars in cash. Total payments to Corvidia Therapeutics shareholders could ultimately amount to 2.1 billion US dollars in cash upon the achievement of certain regulatory and sales milestones by Novo Nordisk.
The transaction will not impact Novo Nordisk’s previously communicated operating profit outlook for 2020. Novo Nordisk will fund the upfront payment from financial reserves and the ongoing share buyback programme will not be impacted.
NYSE: NVS
If you look at my thread have more information about this stock
Novartis AG (NVS) is seeing green these days. Currently, NVS is trading at $88.43 and the avg recommendation for the stock is Strong Buy. while the current analyst price target stands at $104.00.
To add more color to this target, the company’s high over the last year is $99.84 and the low is $69.18. Over the last 52 weeks, NVS is down -11.43% while the S&P 500 is down -0.75%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, NVS reported a profit of $8.99 billion. Novartis AG also saw revenues increase to $12.71 billion. In addition, NVS has free cash flow of $2.29 billion as of 03-2020 The company’s EBITDA came in at $2.74 billion which compares well with its peers.
I just sold 5000 shares of this yesterday and will but more.
Novo Nordisk to acquire Corvidia Therapeutics and expand presence in cardiovascular disease
Category: More News Published on Thursday, 11 June 2020 17:18 Hits: 255
BAGSVAERED, Denmark I June 11, 2020 I Novo Nordisk A/S today announced that it has entered into a definitive agreement to acquire Corvidia Therapeutics Inc., a privately held, clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases.
Corvidia Therapeutics’ lead candidate, ziltivekimab, a fully human monoclonal antibody directed against Interleukin-6 (IL-6), is being developed to reduce the risk of major adverse cardiovascular events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation.
Under the terms of the agreement, Novo Nordisk will acquire all outstanding shares of Corvidia Therapeutics for an upfront payment of 725 million US dollars in cash. Total payments to Corvidia Therapeutics shareholders could ultimately amount to 2.1 billion US dollars in cash upon the achievement of certain regulatory and sales milestones by Novo Nordisk.
The transaction will not impact Novo Nordisk’s previously communicated operating profit outlook for 2020. Novo Nordisk will fund the upfront payment from financial reserves and the ongoing share buyback programme will not be impacted.
Good day and good timing, I bough 3000 NVO in the pre-market and sold at 66 i will buy again on the next dip.
Depends on what the international markets do in the pre-market over the weekend.
Novo Nordisk A/S (NVO ) announced that it has agreed to buy AstraZeneca Plc’s (AZN -) spin-off, Corvidia Therapeutics, for an upfront payment of $725 million in cash. With the acquisition, the company seeks to expand presence across a range of cardiometabolic diseases that are closely linked to Novo Nordisk’s core business within diabetes and obesity. Upon meeting some regulatory and sales milestones, Novo Nordisk will make total payments of $2.1 billion in cash to Corvidia’s shareholders.
Novo Nordisk A/S (NVO ) announced that it has agreed to buy AstraZeneca Plc’s (AZN -) spin-off, Corvidia Therapeutics, for an upfront payment of $725 million in cash. With the acquisition, the company seeks to expand presence across a range of cardiometabolic diseases that are closely linked to Novo Nordisk’s core business within diabetes and obesity. Upon meeting some regulatory and sales milestones, Novo Nordisk will make total payments of $2.1 billion in cash to Corvidia’s shareholders.
